Printer Friendly

Identification of Key Differentially Expressed Transcription Factors in Glioblastoma.

1. Introduction

Glioblastoma (GBM) derives from astrocytes and is the most frequent malignant brain tumor, accounting for 60% of brain cancers in adults [1, 2]. The initial therapeutic approach for GBM is surgery, but it is not curative and is applied normally in conjunction with radiotherapy and chemotherapy [3]. However, tumor progression and recurrence occur in many GBM patients, and their survival may be only 12-15 months, with only 10% probability of surviving for 5 years [4].

Similar to other tumors, the tumorigenesis of GBM is driven by genetic [5], epigenetic, and environmental factors [6]. Dysfunction of transcription factors (TFs), which controls the rate of production of messenger RNA (mRNA), can lead to imbalance in homeostasis and thereby to a variety of diseases, including cancer. Some TFs have been shown to be differentially expressed between GBM and normal brain tissue. In fact, a set of four TFs (LHX2, MEOX2, SNAI2, and ZNF22) has been shown to predict the prognosis of patients with GBM effectively [7]. Aberrant methylation of gene promoters appears to contribute to a broad variety of cancers, including GBM. Generally, hypermethylation in CpG islands promotes carcinogenesis, while hypomethylation activates transcription of oncogenes and reduces transcription of tumor suppressor genes [8]. GBM has been associated with hypermethylation of CpG islands in the genes encoding retinoblastoma protein, phosphatase and tensin homolog, and TP53 [9]. Epigenetic silencing of the gene encoding O6-methylguanine-DNA methyltransferase has been associated with longer survival times in GBM patients treated with alkylating agents [10].

Our understanding of the genetic and epigenetic variations that promote GBM initiation and development is poor. Clarifying these variations may contribute to the identification of potential biomarkers for early diagnosis as well as therapeutic targets. As a step in this direction, the present study applied a bioinformatics approach to analyze the DNA methylation profile of GBM using gene data in The Cancer Genome Atlas (TCGA) [11] and Genotype-Tissue Expression (GTEx) databases.

2. Materials and Methods

2.1. Data Processing. RNA-sequencing data (displayed as read counts) of GBM samples (dataset ID: TCGA-GBM.htseq counts) were downloaded from the TCGA database [12] (https://www.cancer.gov/). The dataset contained 169 GBM tissue samples and 5 paracancer tissue (brain tissue located near cancerous tissue) samples. The mRNAs were extracted according to the Homo_sapiens.GRCh38.97.chr.gtf file, downloaded from the Ensembl website (http://asia.ensembl. org/). The current study adhered to the TCGA publication guidelines and data access policies.

2.2. Screening of Differentially Expressed Genes (DEGs) and Bidirectional Hierarchical Clustering. DEGs between GBM tissue samples and paracancer tissue samples were analyzed using the edgeR package in R software [13]. Fold changes (FCs) in the expression of individual genes were calculated, and genes with [absolute value of log2FC] > 2 and a P value (adjusted by the false discovery rate) <0.001 were considered to be differentially expressed. Bidirectional hierarchical clustering [14] was applied to these DEGs based on Euclidean distance, and the results were displayed as a heat map.

2.3. Functional Enrichment Analysis. The clusterProfiler package of R software [15] was applied to analyze and visualize functional profiles of genes and gene clusters based on Gene Ontology (GO) [16] and the Kyoto Encyclopedia of Genes and Genomes (KEGG) [17]. A P value (adjusted by false discovery rate) <0.05 was considered significant.

2.4. TF Target Enrichment Analysis and TF-Target Gene Network. The Database for Annotation, Visualization, and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) UCSC_TFBS annotation tool (v6.8) was used for TF target enrichment analysis [18]. P values (adjusted by Benjamini method) <0.05 were considered statistically significant. If the enriched TF was also a DEG, which may play a crucial role in the transcriptional regulation of GBM formation, it was defined as a key differentially expressed TF (KDETF). A TF-target gene network was constructed, and Cytoscape software 3.7.1 [19] was used for network visualization.

2.5. Validation of Differential Expression Analysis, Survival Analysis, and Differential Methylation Analysis. The Gene Expression Profiling Interactive Analysis (GEPIA) tool (http://gepia.cancer-pku.cn/) [20] was used to combine the brain gene expression profile from the GTEx database [21] and TCGA paracancer tissue data in order to validate the aberrant expression of the KDETFs. The association of overall survival (OS) and recurrence-free survival (RFS) with the key differentially expressed TFs was analyzed by the Kaplan-Meier survival method and compared using the log-rank test in GEPIA. In addition, 34 GBM and 13 normal samples were extracted from another independent dataset (GSE50161) [22] and used to validate the aberrant expression of the KDETFs.

To explore whether the altered expression of key differentially expressed TFs is caused by aberrant DNA methylation, differentially methylated CpG islands of these TFs were screened using the Wanderer tool (http://maplab. imppc.org/wanderer/) [23]. Differences with P < 0.05 were considered statistically significant.

3. Results

3.1. DEGs and Bidirectional Hierarchical Clustering. According to the cutoff criteria (P < 0.001 and [absolute value of log2FC] >2), 2571 DEGs were identified between the GBM and paracancer tissue samples, including 1029 upregulated and 1542 downregulated genes (Figure 1). Hierarchical clustering showed that the expression patterns of the 100 most upregulated and 100 most downregulated DEGs (Supplementary Table 1) could accurately distinguish GBM and paracancer tissue samples (Figure 2).

3.2. Biological Functions of DEGs. To analyze the biological classification of DEGs, GO and KEGG pathway enrichment analyses were performed. GO annotation results were divided into three groups: cellular components (Figure 3(a)), biological processes (Figure 3(b)), and molecular functions (Figure 3(c)). The most significant GO terms (ranked by P value) are shown in Figure 3. The DEGs were significantly involved in multiple tumor-related and immune-related pathways (Figure 3(d)), such as cell cycle, mitogen-activated protein kinase (MAPK) signaling, leukocyte trans-endothelial migration, and autoimmune thyroid disease.

3.3. A GBM-Related TF-Target Gene Transcriptional Regulatory Network. A total of 174 TFs were enriched based on the analysis of DEGs using the DAVID UCSC_TFBS annotation tool (Supplementary Table 2). Six of these TFs were themselves differentially expressed in GBM and were, therefore, identified as KDETF: homeobox A3 (HOXA3), engrailed homeobox 1 (EN1), Zic family member 1 (ZIC1), and forkhead box D3 (FOXD3) were upregulated, while hepatic leukemia factor (HLF) and early growth response protein 3 (EGR3) were downregulated. A total of 1978 DEGs were enriched in the regulatory networks of these six key differentially expressed TFs. The aberrant expression of some DEGs may be driven by the key differentially expressed TFs. Thus, we constructed a GBM-related TF-target gene transcriptional regulation network based on these six TFs (Figure 4(a)). For clearer visualization, we also provided a regulatory network for each key differentially expressed TF and a subset of 50 of its target genes randomly selected using the sample function in R (Figure 4(b)).

3.4. EGR3 and EN1 Expression Associated with Prognosis in GBM. The aberrant expression of these six key differentially expressed TFs was validated by combining the brain gene expression profile from the GTEx database and data from TCGA paracancer tissue (Figure 5(a)). The correlation between the expression of key differentially expressed TFs and OS or RFS was explored using the GEPIA tool. GBM patients were divided into high and low TF expression groups. High expression of EN1 was associated with significantly shorter OS (Figure 5(b)), while high expression of EGR3 was associated with shorter RFS (Figure 5(c)). The aberrant expression of these six KDETFs was confirmed in the GSE50161 dataset (Figure 6). Analysis with the Wanderer tool showed that methylation of CpG islands in the six KDETFs did not differ significantly between GBM and paracancer tissues (Figure 7), suggesting that differential methylation may not drive aberrant expression of these genes in GBM.

4. Discussion

In GBM samples, 1029 genes were upregulated and 1542 genes were downregulated in comparison with paracancer tissues. These DEGs were predominantly involved in multiple tumor-related and immune-related pathways, such as cell cycle, MAPK signaling, leukocyte trans-endothelial migration, and autoimmune thyroid disease, which may suggest that the occurrence of GBM is associated with an abnormal immune status. In particular, innate immune cells including microglia and macrophages may play a subtype-specific role in GBM by favoring tumor growth and invasion [24]. Besides macrophages, many other immune cells are present in GBM parenchyma, with T cells being, perhaps, the most abundant lymphoid cells. Relatively, few tumor-killing [CD8.sup.+] cytotoxic T cells are present; these cells make up less than a quarter of all [CD3.sup.+] cells [25]. [CD3.sup.+] T cells from GBM patients respond less to direct anti-CD3 stimulation than the corresponding cells from healthy controls in vitro, suggesting immunosuppression in GBM [25].

The aberrant expression of genes in GBM and other cancers maybe at least partly driven by aberrant expression of TFs because these factors turn genes "on" and "off" to ensure their expression in the appropriate cells at the appropriate times [26,27]. Our study demonstrated that six TFs were differentially expressed in GBM: HOXA3, EN1, ZIC1, and FOXD3 were upregulated, while HLF and EGR3 were downregulated. A total of 1978 DEGs were enriched in the regulatory networks of these six keys differentially expressed TFs, which may indicate that the aberrant expression of some DEGs may be regulated by these TFs during the development of GBM. Though we failed to validate the aberrant expression of EGR3 and ZIC1 as there are fewer samples in the GSE50161 dataset, the aberrant expressions of EGR3 and ZIC1 are validated in Figure 5(a) which combined brain gene expression profile from TCGA and GTEx database with a large number of samples. Moreover, we constructed a TF-target gene transcriptional regulatory network for GBM. OS and RFS were both explored for each of the five key genes. However, only EGR3 expression was associated with OS, and EN1 expression was associated with RFS. High expression of EN1 was associated with shorter OS, while high expression of EGR3 was associated with shorter RFS, suggesting that these two TFs may be useful as biomarkers of GBM prognosis. Although little is known about the role of EN1 and EGR3 in GBM, previous work showed that EN1 is a hub gene and that its downregulation significantly reduced the viability of triple-negative breast cancer cell lines [28]. Moreover, EN1 may predict risk of brain metastasis in patients with triple- negative breast cancer [29, 30]. EGR3 expression has been shown to be significantly lower in gastric cancer tissues than in matched nontumor tissues, and patients with lower EGR3 expression show poorer prognosis than those with higher expression [31]. EGR3 is downregulated by microRNA 718, and EGR3 expression is significantly reduced in various hepatocellular carcinoma cell lines and tissues [32].

Methylation in CpG islands in the six KDETFs in our study did not differ significantly between GBM and paracancer tissues, which suggest that their differential expression may not be driven by aberrant methylation. This contrasts with several previous studies linking GBM to aberrant methylation. A previous study proposed that DNA demethylation is involved in the recurrence and progression of GBM [33]. Another study reported that 616 CpG sites differentially methylated between glioblastoma and control brain (nonneoplastic brain tissues obtained from patients undergoing surgery for chronic epilepsy), 25% of which were differentially expressed in a concordant way and that these methylation differences were consistent with observed differences in gene expression [34]. A methylation signature based on eight genes (C9orf64, OSMR, MDK, MARVELD', PTRF, MYD88, BIRC3, and RPP25) was able to predict the survival of GBM patients [35]. Additional abnormally methylated genes have also been identified in GBM: NPY, TNF, FOXA1, KCNC3, and CASP8 [36], and another study identified 251 hypomethylated upregulated genes (Hypo UGs) and 199 hypermethylated downregulated genes (Hyper-DGs) in GBM [33]. Hypo-UGs were involved in regulating signaling associated with immune responses and infection, while Hyper-DGs were involved in regulating synaptic transmission. Three hub genes for Hyper-DGs were identified: somatostatin, neuropeptide Y, and adenylate cyclase 2. Five hub genes for Hypo-UGs were identified: interleukin-8, matrix metalloproteinase (MMP)-9, cyclin-dependent kinase 1, 2'-5'-oligoadenylate synthetase 1, C-XC motif chemokine ligand 10, and MMP2. Overexpression of the following Hypo-UGs was significantly associated with poor prognosis in patients: C-type lectin domain containing 5A, epithelial membrane protein 3, solute carrier family 43 member 3, STEAP3 metalloreductase, tumor necrosis factor [alpha]-induced protein 6, and apolipoprotein B mRNA-editing enzyme catalytic subunit 3G. In contrast to those previous studies, our results suggest that differential expression of the six KDETFs in GBM may not involve differential methylation. These results should be verified in larger datasets and explored further.

The present study may provide new insights into GBM by identifying potential KDETFs and exploring whether differential methylation drives their abnormal expression. At the same time, our conclusions should be treated with caution because our analyses involved a relatively small number of normal samples. In addition, we conducted only bioinformatics analyses, so our results must be verified in experiments with cell lines and clinical samples.

5. Conclusions

The present study comprehensively analyzed GBM gene data using bioinformatic methods, which led to the identification of several key differentially expressed TFs, including HOXA3, EN1, ZIC1, FOXD3, HLF, and EGR3. The findings in this study can improve our understanding of the molecular mechanisms underlying GBM and provide potential biomarkers and even therapeutic targets against the disease.

https://doi.org/10.1155/2020/9235101

Data Availability

The data used to support this study are available publicly in The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO).

Conflicts of Interest

The authors declare no conflicts of interest in this work.

Authors' Contributions

Gang Qin, Beiquan Hu, and Xianfeng Li equally contributed to this work.

Acknowledgments

This study was supported by the Project of Nanning Scientific Research and Technology Development Plan (20193093 and 20183040-2), the Scientific Research Project of Guangxi Health Commission (Z20190376 and Z20190684), and the High-Level Medical Expert Training Program of Guangxi "139" Plan Funding (G201903049). This study was also sponsored by Nanning Excellent Young Scientist Program and Guangxi Beibu Gulf Economic Zone Major Talent Program (RC20190103). The authors would like to thank the Life-Ontology Biological Technology Co., Ltd., for assisting with bioinformatics analysis.

Supplementary Materials

Supplementary Table 1: top 100 up- and downregulated genes. Supplementary Table 2: enrichment of transcription factors based on analysis of differentially expressed genes. (Supplementary Materials)

References

[1] K. Anjum, B. I. Shagufta, S. Q. Abbas et al., "Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review," Biomedicine & Pharmacotherapy, vol. 92, pp. 681-689, 2017.

[2] A. Shergalis, A. Bankhead, U. Luesakul, N. Muangsin, and N. Neamati, "Current challenges and opportunities in treating glioblastoma," Pharmacological Reviews, vol. 70, no. 3, pp. 412-445, 2018.

[3] O. G. Taylor, J. S. Brzozowski, and K. A. Skelding, "Glioblastoma multiforme: an overview of emerging therapeutic targets," Frontiers in Oncology, vol. 9, p. 963, 2019.

[4] O. Gallego, "Nonsurgical treatment of recurrent glioblastoma," Current Oncology, vol. 22, pp. e273-81, 2015.

[5] M. Cao, J. Cai, Y. Yuan et al., "A four-gene signature-derived risk score for glioblastoma: prospects for prognostic and response predictive analyses," Cancer Biology & Medicine, vol. 16, no. 3, pp. 595-605, 2019.

[6] A. O. Sasmita, Y. P. Wong, and A. P. K. Ling, "Biomarkers and therapeutic advances in glioblastoma multiforme," Asia-Pacific Journal of Clinical Oncology, vol. 14, no. 1, pp. 40-51, 2018.

[7] Q. Cheng, C. Huang, H. Cao et al., "A novel prognostic signature of transcription factors for the prediction in patients with GBM," Frontiers in Genetics, vol. 10, p. 906, 2019.

[8] M. D. Long, D. J. Smiraglia, and M. J. Campbell, "The genomic impact of DNA CpG methylation on gene expression; relationships in prostate cancer," Biomolecules, vol. 7, no. 4, 2017.

[9] Y. Zhang, C. Dube, M. Gibert Jr. et al., "The p53 pathway in glioblastoma," Cancers, vol. 10, 2018.

[10] S. Lalezari, A. P. Chou, A. Tran et al., "Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome," Neuro-Oncology, vol. 15, no. 3, pp. 370-381, 2013.

[11] U. R. Chandran, O. P. Medvedeva, M. M. Barmada et al., "TCGA expedition: a data acquisition and management system for TCGA data," PLoS One, vol. 11, no. 10, Article ID e0165395, 2016.

[12] G. B. Mills, J. N. Weinstein, E. A. Collisson et al., "The cancer genome atlas pan-cancer analysis project," Nature Genetics, vol. 45, no. 10, pp. 1113-1120, 2013.

[13] L. Naumann, D. Huscher, J. Detert, M. Spengler, G.-R. Burmester, and F. Buttgereit, "Anti-tumour necrosis factor therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment," Annals of the Rheumatic Diseases, vol. 68, no. 12, pp. 1934-1936, 2009.

[14] G. J. Szekely and M. L. Rizzo, "Hierarchical clustering via joint between-within distances: extending ward's minimum variance method," Journal of Classification, vol. 22, pp. 151-183, 2005.

[15] G. Yu, L.-G. Wang, Y. Han, and Q.-Y. He, "Clusterprofiler: an r package for comparing biological themes among gene clusters," OMICS: A Journal of Integrative Biology, vol. 16, no. 5, pp. 284-287, 2012.

[16] T. Torto-Alalibo, E. Purwantini, J. Lomax, J. C. Setubal, B. Mukhopadhyay, and B. M. Tyler, "Genetic resources for advanced biofuel production described with the gene ontology," Frontiers in Microbiology, vol. 5, p. 528, 2014.

[17] M. Kanehisa, "The KEGG database," in Silico' Simulation of Biological Processes, pp. 91-52, Wiley, Hoboken, NJ, USA, 2002.

[18] G. Dennis Jr., B. T. Sherman, D. A. Hosack et al., "DAVID: database for annotation, visualization, and integrated discovery," Genome Biology, vol. 4, no. 5, 2003.

[19] P. Shannon, A. Markiel, O. Ozier et al., "Cytoscape: a software environment for integrated models of biomolecular interaction networks," Genome Research, vol. 13, no. 11, pp. 2498-2504, 2003.

[20] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "Gepia: a web server for cancer and normal gene expression profiling and interactive analyses," Nucleic Acids Research, vol. 45, no. 1, pp. W98-W102, 2017.

[21] H. F. Moore, J. Thomas, J. Lonsdale et al., "The genotype-tissue expression (GTEx) project," Nature Genetics, vol. 45, pp. 580-585, 2013.

[22] A. M. Griesinger, D. K. Birks, A. M. Donson et al., "Characterization of distinct immunophenotypes across pediatric brain tumor types," The Journal of Immunology, vol. 191, no. 9, pp. 4880-4888, 2013.

[23] A. Diez-Villanueva, I. Mallona, and M. A. Peinado, "Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer," Epigenetics & Chromatin, vol. 8, no. 1, p. 22, 2015.

[24] C. Russo, L. Lisi, L. Tentori, P. Navarra, G. Graziani, and C. Combs, "Exploiting microglial functions for the treatment of glioblastoma," Current Cancer Drug Targets, vol. 17, no. 3, pp. 267-281, 2017.

[25] S. Han, E. Ma, X. Wang et al., "Rescuing defective tumor-infiltrating t-cell proliferation in glioblastoma patients," Oncology Letters, vol. 12, no. 4, pp. 2924-2929, 2016.

[26] M. Karin, "Too many transcription factors: positive and negative interactions," The New Biologist, vol. 2, no. 2, pp. 126-131, 1990.

[27] D. S. Latchman, "Transcription factors: an overview," The International Journal of Biochemistry & Cell Biology, vol. 29, no. 12, pp. 1305-1312, 1997.

[28] Y. J. Kim, M. Sung, E. Oh et al., "Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer," Cancer Biology & Therapy, vol. 19, no. 4, pp. 335-345, 2018.

[29] F. Darbeheshti, N. Rezaei, M. M. Amoli, Y. Mansoori, and J. Tavakkoly Bazzaz, "Integrative analyses of triple negative dysregulated transcripts compared with non-triple negative tumors and their functional and molecular interactions," Journal of Cellular Physiology, vol. 234, no. 12, pp. 22386-22399, 2019.

[30] G. Peluffo, A. Subedee, N. W. Harper et al., "EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis," Cancer Research, vol. 79, no. 16, pp. 4173-4183, 2019.

[31] F. Liao, M.-Y. Ji, L. Shen, S. Qiu, X.-F. Guo, and W.-G. Dong, "Decreased EGR3 expression is related to poor prognosis in patients with gastric cancer," Journal of Molecular Histology, vol. 44, no. 4, pp. 463-468, 2013.

[32] Z.-D. Wang, F.-Y. Qu, Y.-Y. Chen, Z.-S. Ran, H.-Y. Liu, and H.-D. Zhang, "Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells," Journal of Zhejiang University-Science B, vol. 18, no. 1, pp. 27-36, 2017.

[33] M. Zhang, X. Lv, Y. Jiang, G. Li, and Q. Qiao, "Identification of aberrantly methylated differentially expressed genes in glioblastoma multiforme and their association with patient survival," Experimental and Therapeutic Medicine, vol. 18, no. 3, pp. 2140-2152, 2019.

[34] A. Etcheverry, M. Aubry, M. De Tayrac et al., "DNA methylation in glioblastoma: impact on gene expression and clinical outcome," BMC Genomics, vol. 11, no. 1, p. 701, 2010.

[35] W. Wang, Z. Zhao, F. Wu et al., "Bioinformatic analysis of gene expression and methylation regulation in glioblastoma," Journal of Neuro-Oncology, vol. 136, no. 3, pp. 495-503, 2018.

[36] S. Kan, S. Chai, W. Chen, and B. Yu, "DNA methylation profiling identifies potentially significant epigenetically-regulated genes in glioblastoma multiforme," Oncology Letters, vol. 18, no. 2, pp. 1679-1688, 2019.

Gang Qin, (1) Beiquan Hu, (1) Xianfeng Li, (2) Rongjie Li, (2) Youshi Meng, (2) Yimei Wang, (2) Donghua Zou [ID], (2) and Feng Wei [ID] (1)

(1) Department of Neurosurgery, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530022, China

(2) Department of Neurology, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530022, China

Correspondence should be addressed to Donghua Zou; danvor0922@hotmail.com and Feng Wei; 1320333805@qq.com

Received 28 January 2020; Revised 13 May 2020; Accepted 25 May 2020; Published 15 June 2020

Academic Editor: Giandomenico Roviello

Caption: Figure 1: Volcano plot of differentially expressed gene analysis. Red dots represent upregulated genes, blue dots represent downregulated genes, and black dots represent genes not differentially expressed.

Caption: Figure 2: Hierarchical clustering dendrograms of expression patterns of genes differentially expressed between glioblastoma (GBM) and paracancer tissues.

Caption: Figure 3: Functional enrichment analysis of differentially expressed genes in glioblastoma in terms of (a) cellular components, (b) biological processes, (c) molecular functions, and (d) Kyoto Encyclopedia of Genes and Genomes Pathways.

Caption: Figure 4: Transcription factor-target gene regulatory networks in glioblastoma. The networks are shown with (a) all their target genes or (b) a subset of 50 target genes randomly selected using the sample function in R. Red color indicates upregulation, while green color indicates downregulation.

Caption: Figure 5: Validation of aberrant expression and survival analysis. (a) The aberrant expression of the six key differentially expressed transcription factors was validated by combining the brain gene expression profile from Genotype-Tissue Expression database and The Cancer Genome Atlas in paracancer tissues. The asterisk indicates P < 0.01. (b) High expression of EN1 was associated with shorter overall survival of GBM patients. (c) High expression of EGR3 was associated with shorter recurrence-free survival of GBM patients.

Caption: Figure 6: Validation of the aberrant expression of the six key differentially expressed transcription factors in the independent dataset GSE50161.

Caption: Figure 7: Wanderer analysis of CpG island methylation in the six key differentially expressed transcription factors. Methylation patterns did not differ significantly between GBM and paracancerous tissues.
COPYRIGHT 2020 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Qin, Gang; Hu, Beiquan; Li, Xianfeng; Li, Rongjie; Meng, Youshi; Wang, Yimei; Zou, Donghua; Wei, Fen
Publication:Journal of Oncology
Date:Jun 30, 2020
Words:3834
Previous Article:AEBP1 is a Novel Oncogene: Mechanisms of Action and Signaling Pathways.
Next Article:Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |